Page last updated: 2024-11-13

oprozomib

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ONX 0912: antineoplastic; an orally active proteasome inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID25067547
CHEMBL ID2103884
SCHEMBL ID1709971
MeSH IDM000607683

Synonyms (44)

Synonym
oprozomib (usan/inn)
D10318
oprozomib
pr-047
onx-0912
onx 0912
CHEMBL2103884
pr 047
oprozomib [usan:inn]
unii-mz37792y8j
l-serinamide, o-methyl-n-((2-methyl-5-thiazolyl)carbonyl)-l-seryl-o-methyl-n-((1s)-2- ((2r)-2-methyl-2-oxiranyl)-2-oxo-1-(phenylmethyl)ethyl)-
mz37792y8j ,
935888-69-0
o-methyl-n-((2-methylthiazol-5-yl)carbonyl)-l-seryl-o-methyl-n-((1s)-1-benzyl-2-((2r)- 2-methyloxiran-2-yl)-2-oxoethyl)-l-serinamide
bdbm50398607
NCGC00345799-01
oprozomib (onx-0912)
oprozomib [inn]
oprozomib [usan]
oprozomib [who-dd]
gtpl8739
n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide
HY-12113
n-((s)-3-methoxy-1-(((s)-3-methoxy-1-(((s)-1-((r)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide
SWZXEVABPLUDIO-WSZYKNRRSA-N
oprozomib (onx 0912)
n-((s)-3-methoxy-1-((s)-3-methoxy-1-((s)-1-((r)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-ylamino)-1-oxopropan-2-ylamino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide
SCHEMBL1709971
AKOS028109171
J-690398
EX-A332
l-serinamide, o-methyl-n-[(2-methyl-5-thiazolyl)carbonyl]-l-seryl-o-methyl-n-[(1s)-2-[(2r)-2-methyl-
onx0912(oprozomib)
mfcd25976563
DB11991
BCP07603
onx 0912; pr 047; onx-0912; pr-047; onx0912; pr047
Q27088209
AS-17020
nsc-766254
nsc766254
NCGC00345799-04
NCGC00345799-02
DTXSID201025950

Research Excerpts

Overview

Oprozomib is an oral, second-generation, irreversible proteasome inhibitor. It is currently in clinical development for haematologic malignancies, including multiple myeloma.

ExcerptReferenceRelevance
"Oprozomib is an oral, second-generation, irreversible proteasome inhibitor currently in clinical development for haematologic malignancies, including multiple myeloma and other malignancies. "( Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Cutler, RE; Gore, L; Harvey, RD; Mita, A; Ou, Y; Papadopoulos, KP; Pinchasik, DE; Tsimberidou, AM; Wang, Z; Xu, Y, 2019
)
2.2
"Oprozomib is an oral proteasome inhibitor with activity in multiple myeloma (MM). "( Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Boccia, R; Chang, YL; Frye, J; Hari, P; Moreau, P; Paba-Prada, CE; Shain, KH; Voorhees, PM; Zonder, J, 2019
)
2.18

Toxicity

ExcerptReferenceRelevance
" All patients reported ≥1 treatment-emergent adverse event (AE); the most common AEs were gastrointestinal."( Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Boccia, R; Chang, YL; Frye, J; Hari, P; Moreau, P; Paba-Prada, CE; Shain, KH; Voorhees, PM; Zonder, J, 2019
)
0.74

Pharmacokinetics

ExcerptReferenceRelevance
" inclusion/exclusion criteria, combination study design), we used human hepatocyte data and physiologically-based pharmacokinetic (PBPK) modelling to predict its CYP3A4-mediated DDI potential."( Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Cutler, RE; Gore, L; Harvey, RD; Mita, A; Ou, Y; Papadopoulos, KP; Pinchasik, DE; Tsimberidou, AM; Wang, Z; Xu, Y, 2019
)
0.76

Compound-Compound Interactions

ExcerptReferenceRelevance
" These studies provide further support for clinical trials evaluating OPZ in combination with Pom and Dex."( Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex).
Berenson, JR; Chen, H; Gillespie, A; Li, M; Sanchez, E; Tang, G; Wang, CS, 2017
)
0.7
" This unusual property elicits uncertainty regarding the optimal approach for predicting its drug-drug interaction (DDI) risk."( Physiologically-based pharmacokinetic modelling to predict oprozomib CYP3A drug-drug interaction potential in patients with advanced malignancies.
Cutler, RE; Gore, L; Harvey, RD; Mita, A; Ou, Y; Papadopoulos, KP; Pinchasik, DE; Tsimberidou, AM; Wang, Z; Xu, Y, 2019
)
0.76

Bioavailability

Next-generation orally bioavailable irreversible proteasome inhibitor oprozomib was developed. ONX 0912 (oproZomib) is an oral bioavailable derivative. CarfilzomIB and its orallyBioavailable structural analog opro Zomib are second-generation, highly-selective, proteasomesome inhibitors.

ExcerptReferenceRelevance
" ONX 0912 (oprozomib) is an orally bioavailable derivative."( Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy.
Chan, ET; DeLancey, HM; Freilino, ML; Grandis, JR; Johnson, DE; Kirk, CJ; Li, C; Thomas, SM; Zang, Y, 2012
)
0.77
" Carfilzomib and its orally bioavailable structural analog oprozomib are second-generation, highly-selective, proteasome inhibitors."( Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors.
Johnson, DE; Kirk, CJ; Zang, Y, 2014
)
0.99
" Recently, the next-generation orally bioavailable irreversible proteasome inhibitor oprozomib was developed."( Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma.
Bogaerts, E; Coucke, C; Devisscher, L; Geerts, A; Laukens, D; Libbrecht, L; Paridaens, A; Raevens, S; Van Steenkiste, C; Van Vlierberghe, H; Vandewynckel, YP; Vandierendonck, A; Verhelst, X, 2016
)
0.93
" Many recent studies have investigated the safety of orally bioavailable proteasome inhibitors, such as ixazomib and oprozomib."( Proteasome inhibitor-induced gastrointestinal toxicity.
Gibson, RJ; Stansborough, RL, 2017
)
0.66
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" In phases 1b and 2, ORR across dosing cohorts (210-330 mg) for the 2/7 schedule was 58."( Efficacy and safety results from a phase 1b/2, multicenter, open-label study of oprozomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
Boccia, R; Chang, YL; Frye, J; Hari, P; Moreau, P; Paba-Prada, CE; Shain, KH; Voorhees, PM; Zonder, J, 2019
)
0.74
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (25)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency1.17700.00308.794948.0869AID1347053
PPM1D proteinHomo sapiens (human)Potency0.05230.00529.466132.9993AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency10.68400.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency0.17020.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency1.17700.00308.794948.0869AID1347053
Interferon betaHomo sapiens (human)Potency0.05230.00339.158239.8107AID1347411
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Proteasome subunit beta type-11Homo sapiens (human)IC50 (µMol)0.02350.00130.70995.0000AID1763827
Proteasome subunit alpha type-7Homo sapiens (human)IC50 (µMol)0.02350.00130.70995.0000AID1763827
Proteasome subunit beta type-1Homo sapiens (human)IC50 (µMol)0.02350.00060.73766.3700AID1763827
Proteasome subunit alpha type-1Homo sapiens (human)IC50 (µMol)0.02350.00130.70995.0000AID1763827
Proteasome subunit alpha type-2Homo sapiens (human)IC50 (µMol)0.02350.00130.70995.0000AID1763827
Proteasome subunit alpha type-3Homo sapiens (human)IC50 (µMol)0.02350.00130.70995.0000AID1763827
Proteasome subunit alpha type-4Homo sapiens (human)IC50 (µMol)0.02350.00130.70995.0000AID1763827
Proteasome subunit beta type-8Homo sapiens (human)IC50 (µMol)0.03850.00130.36985.0000AID1604187; AID1763827; AID706734
Proteasome subunit beta type-9Homo sapiens (human)IC50 (µMol)0.02350.00100.76115.0000AID1763827
Proteasome subunit alpha type-5Homo sapiens (human)IC50 (µMol)0.02350.00130.70995.0000AID1763827
Proteasome subunit beta type-4Homo sapiens (human)IC50 (µMol)0.02350.00130.70995.0000AID1763827
Proteasome subunit beta type-6Homo sapiens (human)IC50 (µMol)0.02350.00130.69125.0000AID1763827
Proteasome subunit beta type-5Homo sapiens (human)IC50 (µMol)0.03270.00050.939410.0000AID1573578; AID1604186; AID1613994; AID1763827; AID706735
Proteasome subunit beta type-10Homo sapiens (human)IC50 (µMol)0.02350.00130.81515.0000AID1763827
Proteasome subunit beta type-3Homo sapiens (human)IC50 (µMol)0.02350.00130.70995.0000AID1763827
Proteasome subunit beta type-2Homo sapiens (human)IC50 (µMol)0.02350.00131.39067.9540AID1763827
Proteasome subunit alpha type-6Homo sapiens (human)IC50 (µMol)0.02350.00130.70995.0000AID1763827
Proteasome subunit alpha-type 8Homo sapiens (human)IC50 (µMol)0.02350.00130.70995.0000AID1763827
Proteasome subunit beta type-7Homo sapiens (human)IC50 (µMol)0.02350.00130.68435.0000AID1763827
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (53)

Processvia Protein(s)Taxonomy
proteolysisProteasome subunit beta type-11Homo sapiens (human)
T cell differentiation in thymusProteasome subunit beta type-11Homo sapiens (human)
CD8-positive, alpha-beta T cell differentiationProteasome subunit beta type-11Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-11Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-7Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit beta type-1Homo sapiens (human)
immune system processProteasome subunit alpha type-1Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProteasome subunit alpha type-1Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-1Homo sapiens (human)
response to virusProteasome subunit alpha type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-3Homo sapiens (human)
regulation of endopeptidase activityProteasome subunit alpha type-3Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-4Homo sapiens (human)
antigen processing and presentationProteasome subunit beta type-8Homo sapiens (human)
fat cell differentiationProteasome subunit beta type-8Homo sapiens (human)
regulation of endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-8Homo sapiens (human)
immune system processProteasome subunit beta type-9Homo sapiens (human)
regulation of cysteine-type endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-9Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-5Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusProteasome subunit beta type-4Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-4Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-6Homo sapiens (human)
proteolysisProteasome subunit beta type-5Homo sapiens (human)
response to oxidative stressProteasome subunit beta type-5Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-5Homo sapiens (human)
cell morphogenesisProteasome subunit beta type-10Homo sapiens (human)
humoral immune responseProteasome subunit beta type-10Homo sapiens (human)
T cell proliferationProteasome subunit beta type-10Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-10Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-3Homo sapiens (human)
response to organonitrogen compoundProteasome subunit beta type-2Homo sapiens (human)
response to organic cyclic compoundProteasome subunit beta type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-2Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
regulation of inflammatory responseProteasome subunit alpha type-6Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProteasome subunit alpha type-6Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
spermatogenesisProteasome subunit alpha-type 8Homo sapiens (human)
proteasomal protein catabolic processProteasome subunit alpha-type 8Homo sapiens (human)
cell differentiationProteasome subunit alpha-type 8Homo sapiens (human)
meiotic cell cycleProteasome subunit alpha-type 8Homo sapiens (human)
regulation of meiosis IProteasome subunit alpha-type 8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha-type 8Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit beta type-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
threonine-type endopeptidase activityProteasome subunit beta type-11Homo sapiens (human)
protein bindingProteasome subunit beta type-11Homo sapiens (human)
peptidase activityProteasome subunit beta type-11Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-11Homo sapiens (human)
protein bindingProteasome subunit alpha type-7Homo sapiens (human)
identical protein bindingProteasome subunit alpha type-7Homo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
protein bindingProteasome subunit beta type-1Homo sapiens (human)
lipopolysaccharide bindingProteasome subunit alpha type-1Homo sapiens (human)
protein bindingProteasome subunit alpha type-1Homo sapiens (human)
protein bindingProteasome subunit alpha type-2Homo sapiens (human)
protein bindingProteasome subunit alpha type-3Homo sapiens (human)
ubiquitin protein ligase bindingProteasome subunit alpha type-3Homo sapiens (human)
protein bindingProteasome subunit alpha type-4Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
protein bindingProteasome subunit beta type-8Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-8Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
protein bindingProteasome subunit beta type-9Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-9Homo sapiens (human)
protein bindingProteasome subunit alpha type-5Homo sapiens (human)
lipopolysaccharide bindingProteasome subunit beta type-4Homo sapiens (human)
protein bindingProteasome subunit beta type-4Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-6Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-6Homo sapiens (human)
protein bindingProteasome subunit beta type-6Homo sapiens (human)
cadherin bindingProteasome subunit beta type-6Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
protein bindingProteasome subunit beta type-5Homo sapiens (human)
peptidase activityProteasome subunit beta type-5Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-5Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-10Homo sapiens (human)
protein bindingProteasome subunit beta type-10Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-10Homo sapiens (human)
protein bindingProteasome subunit beta type-3Homo sapiens (human)
protein bindingProteasome subunit beta type-2Homo sapiens (human)
RNA bindingProteasome subunit alpha type-6Homo sapiens (human)
endopeptidase activityProteasome subunit alpha type-6Homo sapiens (human)
protein bindingProteasome subunit alpha type-6Homo sapiens (human)
purine ribonucleoside triphosphate bindingProteasome subunit alpha type-6Homo sapiens (human)
NF-kappaB bindingProteasome subunit alpha type-6Homo sapiens (human)
threonine-type endopeptidase activityProteasome subunit beta type-7Homo sapiens (human)
protein bindingProteasome subunit beta type-7Homo sapiens (human)
endopeptidase activityProteasome subunit beta type-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
cytosolProteasome subunit beta type-11Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-11Homo sapiens (human)
nucleusProteasome subunit beta type-11Homo sapiens (human)
cytosolProteasome subunit beta type-11Homo sapiens (human)
nucleusProteasome subunit alpha type-7Homo sapiens (human)
cytoplasmProteasome subunit alpha type-7Homo sapiens (human)
proteasome complexProteasome subunit alpha type-7Homo sapiens (human)
nucleusProteasome subunit alpha type-7Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-7Homo sapiens (human)
cytosolProteasome subunit alpha type-7Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-7Homo sapiens (human)
postsynapseProteasome subunit alpha type-7Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-7Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-7Homo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
nucleusProteasome subunit beta type-1Homo sapiens (human)
cytoplasmProteasome subunit beta type-1Homo sapiens (human)
proteasome complexProteasome subunit beta type-1Homo sapiens (human)
extracellular regionProteasome subunit beta type-1Homo sapiens (human)
nucleusProteasome subunit beta type-1Homo sapiens (human)
nucleoplasmProteasome subunit beta type-1Homo sapiens (human)
cytosolProteasome subunit beta type-1Homo sapiens (human)
secretory granule lumenProteasome subunit beta type-1Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-1Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit beta type-1Homo sapiens (human)
proteasome core complexProteasome subunit beta type-1Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-1Homo sapiens (human)
nucleusProteasome subunit alpha type-1Homo sapiens (human)
cytoplasmProteasome subunit alpha type-1Homo sapiens (human)
proteasome complexProteasome subunit alpha type-1Homo sapiens (human)
nucleusProteasome subunit alpha type-1Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-1Homo sapiens (human)
centrosomeProteasome subunit alpha type-1Homo sapiens (human)
cytosolProteasome subunit alpha type-1Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-1Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-1Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-1Homo sapiens (human)
nucleusProteasome subunit alpha type-2Homo sapiens (human)
cytoplasmProteasome subunit alpha type-2Homo sapiens (human)
proteasome complexProteasome subunit alpha type-2Homo sapiens (human)
P-bodyProteasome subunit alpha type-2Homo sapiens (human)
extracellular regionProteasome subunit alpha type-2Homo sapiens (human)
nucleusProteasome subunit alpha type-2Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-2Homo sapiens (human)
cytosolProteasome subunit alpha type-2Homo sapiens (human)
secretory granule lumenProteasome subunit alpha type-2Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-2Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit alpha type-2Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-2Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-2Homo sapiens (human)
nucleusProteasome subunit alpha type-3Homo sapiens (human)
cytoplasmProteasome subunit alpha type-3Homo sapiens (human)
proteasome complexProteasome subunit alpha type-3Homo sapiens (human)
nucleusProteasome subunit alpha type-3Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-3Homo sapiens (human)
cytoplasmProteasome subunit alpha type-3Homo sapiens (human)
cytosolProteasome subunit alpha type-3Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-3Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-3Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-3Homo sapiens (human)
synapseProteasome subunit alpha type-3Homo sapiens (human)
nucleusProteasome subunit alpha type-4Homo sapiens (human)
cytoplasmProteasome subunit alpha type-4Homo sapiens (human)
proteasome complexProteasome subunit alpha type-4Homo sapiens (human)
P-bodyProteasome subunit alpha type-4Homo sapiens (human)
nucleusProteasome subunit alpha type-4Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-4Homo sapiens (human)
cytosolProteasome subunit alpha type-4Homo sapiens (human)
intracellular membrane-bounded organelleProteasome subunit alpha type-4Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-4Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-4Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-4Homo sapiens (human)
cytosolProteasome subunit alpha type-4Homo sapiens (human)
nucleoplasmProteasome subunit beta type-8Homo sapiens (human)
cytosolProteasome subunit beta type-8Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-8Homo sapiens (human)
proteasome complexProteasome subunit beta type-8Homo sapiens (human)
proteasome core complexProteasome subunit beta type-8Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-8Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-8Homo sapiens (human)
nucleusProteasome subunit beta type-8Homo sapiens (human)
cytosolProteasome subunit beta type-8Homo sapiens (human)
nucleoplasmProteasome subunit beta type-9Homo sapiens (human)
cytosolProteasome subunit beta type-9Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-9Homo sapiens (human)
proteasome complexProteasome subunit beta type-9Homo sapiens (human)
proteasome core complexProteasome subunit beta type-9Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-9Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-9Homo sapiens (human)
cytosolProteasome subunit beta type-9Homo sapiens (human)
nucleusProteasome subunit beta type-9Homo sapiens (human)
nucleusProteasome subunit alpha type-5Homo sapiens (human)
cytoplasmProteasome subunit alpha type-5Homo sapiens (human)
proteasome complexProteasome subunit alpha type-5Homo sapiens (human)
extracellular regionProteasome subunit alpha type-5Homo sapiens (human)
nucleusProteasome subunit alpha type-5Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-5Homo sapiens (human)
cytosolProteasome subunit alpha type-5Homo sapiens (human)
secretory granule lumenProteasome subunit alpha type-5Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-5Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit alpha type-5Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-5Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-5Homo sapiens (human)
nucleusProteasome subunit beta type-4Homo sapiens (human)
cytoplasmProteasome subunit beta type-4Homo sapiens (human)
proteasome complexProteasome subunit beta type-4Homo sapiens (human)
nucleusProteasome subunit beta type-4Homo sapiens (human)
nucleoplasmProteasome subunit beta type-4Homo sapiens (human)
mitochondrionProteasome subunit beta type-4Homo sapiens (human)
cytosolProteasome subunit beta type-4Homo sapiens (human)
ciliary basal bodyProteasome subunit beta type-4Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-4Homo sapiens (human)
proteasome core complexProteasome subunit beta type-4Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-4Homo sapiens (human)
cytosolProteasome subunit beta type-4Homo sapiens (human)
nucleusProteasome subunit beta type-6Homo sapiens (human)
cytoplasmProteasome subunit beta type-6Homo sapiens (human)
proteasome complexProteasome subunit beta type-6Homo sapiens (human)
nucleusProteasome subunit beta type-6Homo sapiens (human)
nucleoplasmProteasome subunit beta type-6Homo sapiens (human)
mitochondrionProteasome subunit beta type-6Homo sapiens (human)
cytosolProteasome subunit beta type-6Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-6Homo sapiens (human)
proteasome core complexProteasome subunit beta type-6Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-6Homo sapiens (human)
cytosolProteasome subunit beta type-6Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
cytoplasmProteasome subunit beta type-5Homo sapiens (human)
proteasome complexProteasome subunit beta type-5Homo sapiens (human)
nucleusProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-5Homo sapiens (human)
centrosomeProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-5Homo sapiens (human)
proteasome core complexProteasome subunit beta type-5Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-5Homo sapiens (human)
cytosolProteasome subunit beta type-5Homo sapiens (human)
nucleoplasmProteasome subunit beta type-10Homo sapiens (human)
cytosolProteasome subunit beta type-10Homo sapiens (human)
proteasome complexProteasome subunit beta type-10Homo sapiens (human)
proteasome core complexProteasome subunit beta type-10Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-10Homo sapiens (human)
spermatoproteasome complexProteasome subunit beta type-10Homo sapiens (human)
cytosolProteasome subunit beta type-10Homo sapiens (human)
nucleusProteasome subunit beta type-10Homo sapiens (human)
nucleusProteasome subunit beta type-3Homo sapiens (human)
cytoplasmProteasome subunit beta type-3Homo sapiens (human)
proteasome complexProteasome subunit beta type-3Homo sapiens (human)
nucleusProteasome subunit beta type-3Homo sapiens (human)
nucleoplasmProteasome subunit beta type-3Homo sapiens (human)
cytosolProteasome subunit beta type-3Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-3Homo sapiens (human)
proteasome core complexProteasome subunit beta type-3Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-3Homo sapiens (human)
cytosolProteasome subunit beta type-3Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
cytoplasmProteasome subunit beta type-2Homo sapiens (human)
proteasome complexProteasome subunit beta type-2Homo sapiens (human)
nucleusProteasome subunit beta type-2Homo sapiens (human)
nucleoplasmProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
membraneProteasome subunit beta type-2Homo sapiens (human)
extracellular exosomeProteasome subunit beta type-2Homo sapiens (human)
proteasome core complexProteasome subunit beta type-2Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-2Homo sapiens (human)
cytosolProteasome subunit beta type-2Homo sapiens (human)
nucleusProteasome subunit alpha type-6Homo sapiens (human)
cytoplasmProteasome subunit alpha type-6Homo sapiens (human)
proteasome complexProteasome subunit alpha type-6Homo sapiens (human)
P-bodyProteasome subunit alpha type-6Homo sapiens (human)
nucleusProteasome subunit alpha type-6Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-6Homo sapiens (human)
cytosolProteasome subunit alpha type-6Homo sapiens (human)
ribosomeProteasome subunit alpha type-6Homo sapiens (human)
nuclear matrixProteasome subunit alpha type-6Homo sapiens (human)
myofibrilProteasome subunit alpha type-6Homo sapiens (human)
sarcomereProteasome subunit alpha type-6Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-6Homo sapiens (human)
nucleusProteasome subunit alpha-type 8Homo sapiens (human)
cytosolProteasome subunit alpha-type 8Homo sapiens (human)
extracellular exosomeProteasome subunit alpha-type 8Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha-type 8Homo sapiens (human)
spermatoproteasome complexProteasome subunit alpha-type 8Homo sapiens (human)
nucleusProteasome subunit alpha-type 8Homo sapiens (human)
nucleusProteasome subunit beta type-7Homo sapiens (human)
cytoplasmProteasome subunit beta type-7Homo sapiens (human)
proteasome complexProteasome subunit beta type-7Homo sapiens (human)
extracellular regionProteasome subunit beta type-7Homo sapiens (human)
nucleusProteasome subunit beta type-7Homo sapiens (human)
nucleoplasmProteasome subunit beta type-7Homo sapiens (human)
cytosolProteasome subunit beta type-7Homo sapiens (human)
nuclear bodyProteasome subunit beta type-7Homo sapiens (human)
secretory granule lumenProteasome subunit beta type-7Homo sapiens (human)
ficolin-1-rich granule lumenProteasome subunit beta type-7Homo sapiens (human)
proteasome core complexProteasome subunit beta type-7Homo sapiens (human)
proteasome core complex, beta-subunit complexProteasome subunit beta type-7Homo sapiens (human)
cytosolProteasome subunit beta type-7Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (86)

Assay IDTitleYearJournalArticle
AID706735Irreversible inhibition of constitutive 20S proteasome subunit beta5 chymotrypsin-like activity in human WM cells using suc-LLVY-amc as substrate after 2 hrs by fluorescence assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID1573578Inhibition of human 20S proteasome chymotrypsin-like activity using Suc-Leu-Leu-Val-Tyr-AMC as substrate pretreated for 15 mins followed by substrate addition by fluorescence assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1604190Selectivity index, ratio of IC50 for 20S proteasome beta 5c (unknown origin) to IC50 for 20S proteasome beta 5i (unknown origin)2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID1613997Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.
AID1573579Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTS assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1604187Inhibition of 20S proteasome beta 5i (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID706507P-gp-mediated drug resistance in human CEM/VLB cells relative to control2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID1573590Volume of distribution at steady state in ICR mouse at 5 mg/kg, iv by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1613994Inhibition of human hepatic cell derived 20s constitutive proteasome beta5 chymotrypsin-like activity using Suc-WLA-AMC as substrate preincubated for 15 mins followed by substrate addition and measured after 60 mins by fluorescence assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.
AID1573594Tmax in ICR mouse at 25 mg/kg, po via gavage by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1613996Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.
AID706517Resistance factor, ratio of IC50 for 100 nM bortezonib-resistant human RPMI8226 cells harboring proteosome subunit beta5 A49T mutant to IC50 for wild type human RPMI8226 cells2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID1573595AUC (0 to t) in ICR mouse at 25 mg/kg, po via gavage after 1 hr by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1573583Metabolic stability in mouse liver microsomes assessed as parent compound remaining at 100 uM after 30 mins by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1573589Clearance in ICR mouse at 5 mg/kg, iv by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1763827Inhibition of chymotrypsin-like activity of human 20S proteasome using Suc-Leu-Leu-Val-Tyr-AMC as substrate preincubated for 10 mins followed by substrate addition measured after 1 hr by fluorescence based spectrofluorimeter assay2021Bioorganic & medicinal chemistry, 06-15, Volume: 40Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
AID1763830Metabolic stability in human liver microsomes assessed as half life2021Bioorganic & medicinal chemistry, 06-15, Volume: 40Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
AID1573593Cmax in ICR mouse at 25 mg/kg, po via gavage by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1573596Oral bioavailability in ICR mouse at 25 mg/kg via gavage by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1763832Metabolic stability in mouse liver microsomes assessed as half life2021Bioorganic & medicinal chemistry, 06-15, Volume: 40Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
AID1573581Antiproliferative activity against human MV4-11 cells after 72 hrs by MTS assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1573580Antiproliferative activity against human MM1S cells after 72 hrs by MTS assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1763829Cytotoxicity activity against human RPMI-8226 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay2021Bioorganic & medicinal chemistry, 06-15, Volume: 40Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
AID1573585In vivo inhibition of 20S proteasome chymotrypsin-like activity in Balb/c mouse blood at 30 mg/kg, po measured at 2 to 24 hrs post dose using LLVY-AMC as substrate by fluorescence assay2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1613998Antiproliferative activity against human MV4-11 cells after 72 hrs by MTS assay2019European journal of medicinal chemistry, Feb-15, Volume: 164Exploration of novel macrocyclic dipeptide N-benzyl amides as proteasome inhibitors.
AID706734Irreversible inhibition of inducible 20S proteasome subunit beta5i chymotrypsin-like activity in human WM cells using suc-LLVY-amc as substrate after 2 hrs by fluorescence assay2012Journal of medicinal chemistry, Dec-13, Volume: 55, Issue:23
Molecular mechanisms of acquired proteasome inhibitor resistance.
AID1763828Cytotoxicity activity against human U266B cells assessed as reduction in cell viability measured after 72 hrs by MTS assay2021Bioorganic & medicinal chemistry, 06-15, Volume: 40Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
AID1604186Inhibition of 20S proteasome beta 5c (unknown origin) after 1 hr by fluorescence based assay2019European journal of medicinal chemistry, Nov-15, Volume: 182Immunoproteasome-selective inhibitors: An overview of recent developments as potential drugs for hematologic malignancies and autoimmune diseases.
AID1763842Toxicity in nude mouse xenografted with human RPMI-8226 cells assessed as body weight loss at 50 to 100 mg/kg, po administered biweekly for 21 days2021Bioorganic & medicinal chemistry, 06-15, Volume: 40Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
AID1573591Half life in ICR mouse at 5 mg/kg, iv by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1763831Metabolic stability in rat liver microsomes assessed as half life2021Bioorganic & medicinal chemistry, 06-15, Volume: 40Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
AID1763843Antitumor activity against human RPMI-8226 cells xenografted in nude mouse assessed as reduction in tumor volume at 50 mg/kg, po for 21 days2021Bioorganic & medicinal chemistry, 06-15, Volume: 40Discovery of novel tripeptide propylene oxide proteasome inhibitors for the treatment of multiple myeloma.
AID1573592AUC (0 to t) in ICR mouse at 5 mg/kg, iv after 1 hr by LC-MS/MS analysis2018Journal of medicinal chemistry, 10-25, Volume: 61, Issue:20
Development of Macrocyclic Peptides Containing Epoxyketone with Oral Availability as Proteasome Inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (50)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's38 (76.00)24.3611
2020's12 (24.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.22

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.22 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index6.91 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.22)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (9.80%)5.53%
Reviews7 (13.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (76.47%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]